Omnigene Medical Technologies

Omnigene Medical Technologies launches Gut Restore Program in Madrid

MADRID – June 12, 2024:

 

Omnigene Medical Technologies launches the Gut Restore Program in Madrid through an executive partnership agreement with Dr Pedro Luis González Sanz.  Dr González Sanz is a Physician Coach providing a unique cellular Recovery & Regeneration process based  on epigenetics, bio-regulation through peptides and lifestyle medicine.

The Gut Restore Program is a data-driven approach based on a CE-IVD dysbiosis test gaining a deep understanding of intestinal microbiota associated with intestinal inflammation.  The standardized GA-map® Test is based on a pre-determined targets approach (PDT)and is establishing itself as a valuable tool in routine diagnostics.

Dr Pedro Luis Gonzalez Sanz

Omnigene Medical Technologies Ltd. and Izon Science Ltd enter a product development agreement to innovate technology workflow for liquid biopsies (M3PROFILER)

MALTA – Feb 18, 2024: 

Omnigene Medical Technologies Ltd is developing a test using extracellular vesicles to diagnose and monitor colorectal cancer.  Izon science Ltd and Omnigene MT wish to collaborate on the development of a sample processing kit suitable for widescale clinical use.  The research and development is funded under the M3PROFILER project funded by the Malta Council for Science and Technology (Technology Development Program).  


Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market

OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd. (“Omnigene”), a Malta-based biotechnology company, providing advisory services within several therapeutic areas as cancer and neuroscience. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test, a CE-marked standardized gut microbiome test as a service to the UEA.

Gut microbiome profiling is increasingly required in the field of precision medicine as a surrogate endpoint or exploratory biomarker in research. This is due both to the impact of the gut microbiome on our health and pharmaceuticals that can affect the microbiota composition itself. GA provides the first CE-marked and standardized microbiome test to profile and compare an imbalanced microbiota to healthy references. The standardized GA-map® Test is based on a pre-determined targets approach (PDT)and is establishing itself as a valuable tool in drug development, clinical research, and routine diagnostics.

The demand for the inclusion of gut microbiome assessments in clinics and academic research is rapidly increasing globally and the market in the UEA follows the same trend. Together with Omnigene, GA can now offer its CE-marked standardized gut microbiome test to the UAE market and meet the growing demand. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test as a service to the UAE market. The service offering will also target clinical research customers and medical customers.

Claudine Grech Spiteri, Executive Director, Omnigene, comments: “We are committed to identifying and solving clinical needs to promote patient quality of life. By launching the microbiome profiling test from GA, we will strengthen our offerings to this rapidly growing precision medicine market. Our ambition is to expand and accelerate business in the UAE and we will soon enter the market with this clinical microbiome test powered by the GA-map® technology”

Ronny Hermansen, CEO, Genetic Analysis, comments: “GA is proud to have Omnigene Medical Technologies Ltd as a partner. The GA-map® platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation We believe microbiome testing will soon be a game-changer in medicine and the distribution agreement is well in line with our business strategy to expand to new markets.”